Top

01-07-2017 | Rheumatoid arthritis | Article

Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature

Journal: Clinical Rheumatology

Authors: Gonçalo Boleto, Moustapha Dramé, Isabelle Lambrecht, Jean-Paul Eschard, Jean-Hugues Salmon

Publisher: Springer London

Abstract

The aim of this study was to evaluate the structural effect of denosumab on patients with rheumatoid arthritis (RA). We performed a systematic review of the literature in the following databases: PubMed, Cochrane, Web of Science, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform. All studies evaluating the structural effect of denosumab on RA and meeting predefined criteria were included. Data regarding disease activity, progression of joint damage, joint space narrowing, and safety were recorded. Among 168 studies identified, only 4 were finally included in this review, involving a total of 687 patients. These 4 studies showed that denosumab is effective on joint damage at 6 and 12 months as compared to placebo, alendronate, and biological disease-modifying anti-rheumatic drugs (bDMARDs) alone. No effect was observed in terms of joint space narrowing, and DAS28 and HAQ scores remained unchanged. No case of osteonecrosis of the jaw or atypical fracture was recorded, and safety was similar in both denosumab and control groups. Denosumab appears to be effective on joint erosion at 6 and 12 months in patients with RA meeting the ACR criteria, treated or not by a biologic, with excellent safety.

Furst DE, Emery P (2014) Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatol Oxf Engl. 53(9):1560–1569CrossRef

Lorenzo J, Horowitz M, Choi Y (2008) Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29(4):403–440CrossRefPubMedPubMedCentral

Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS (2005) Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1(1):47–54CrossRefPubMed

Tanaka S (2013) Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World J Orthop 4(1):1–6CrossRefPubMedPubMedCentral

Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y et al (2001) TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159(5):1689–1699CrossRefPubMedPubMedCentral

Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66(12):1139–1146CrossRefPubMedPubMedCentral

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMed

Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161–3169CrossRefPubMed

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TLJ, Saad F et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755CrossRefPubMedPubMedCentral

10.

Takahashi K, Setoguchi T, Tawaratsumida H, Arishima Y, Tominaga H, Ishidou Y et al (2015) Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics. BMC Musculoskelet Disord 16:269CrossRefPubMedPubMedCentral

11.

Hoes JN, Bultink IEM, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16(4):559–571CrossRefPubMed

12.

Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299–1309CrossRefPubMed

13.

Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L et al (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69(5):872–875CrossRefPubMed

14.

Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R et al (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res 62(4):569–574CrossRef

15.

Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R (2010) Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res 62(4):537–544CrossRef

16.

Schett G (2007) Erosive arthritis. Arthritis Res Ther 9(Suppl 1):S2CrossRefPubMedPubMedCentral

17.

Døhn UM, Ejbjerg BJ, Hasselquist M, Narvestad E, Møller J, Thomsen HS et al (2008) Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography. Arthritis Res Ther. 10(1):R25CrossRefPubMedPubMedCentral

18.

Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N, Bacchetta J, Miossec P et al (2010) Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Ann Rheum Dis 69(9):1671–1676CrossRefPubMed

19.

PRISMA [Internet]. [cited 2017 Feb 19]. Available from: http://www.prisma-statement.org/

20.

PICO ontology | Cochrane Linked Data [Internet]. [cited 2017 Feb 19]. Available from: /pico-ontology

21.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed

22.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRefPubMed

23.

Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M et al (1985) How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28(12):1326–1335CrossRefPubMed

24.

van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27(1):261–263PubMed

25.

Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48CrossRefPubMed

26.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735CrossRefPubMed

27.

Ramey DR, Raynauld JP, Fries JF (1992) The health assessment questionnaire 1992: status and review. Arthritis Care Res Off J Arthritis Health Prof Assoc 5(3):119–129CrossRef

28.

Cochrane Handbook for Systematic Reviews of Interventions - Handbook4.2.6Sep2006.pdf [Internet]. [cited 2016 Feb 7]. Available from: http://community.cochrane.org/sites/default/files/uploads/Handbook4.2.6Sep2006.pdf

29.

Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T et al (2015) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 19

30.

Yue J (2016) Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study. Arthritis Care Res Hoboken

31.

Hasegawa T, Kaneko Y, Izumi K, Takeuchi T (2016) Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. Jt Bone Spine Rev Rhum. 28

32.

Gaujoux-Viala C, Paternotte S, Combe B, Dougados M (2012) Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. Rheumatol Oxf Engl 51(9):1648–1654CrossRef

33.

Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I (2005 Nov) Low-dose prednisolone in addition to the initial disease-modifying anti-rheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52(11):3360–3370CrossRefPubMed

34.

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment - Full Text View - ClinicalTrials.gov [Internet]. [cited 2016 Jan 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01973569?term=denosumab+and+rheumatoid+arthritis&rank=2

35.

Koike T, Inui K (2015) How can the treatment of rheumatoid arthritis be improved in Japan? Int J Clin Rheumatol 10(4):235–244CrossRef

36.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509CrossRefPubMed

37.

Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68(1):1–25CrossRef

38.

Mok CC, Tam LS, Chan TH, Lee GKW, Li EKM (2011) Hong Kong Society of Rheumatology. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol 30(3):303–312CrossRefPubMed

39.

Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME (2014) Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 6:CD000957

40.

Geusens P (2012) The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 4(4):225–233CrossRefPubMedPubMedCentral

41.

Sharp JT, Wolfe F, Mitchell DM, Bloch DA (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 34(6):660–668CrossRefPubMed

42.

Smolen JS, Van Der Heijde DMFM, St Clair EW, Emery P, Bathon JM, Keystone E et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702–710CrossRefPubMed

43.

Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D et al (2009) Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 68(10):1535–1340CrossRefPubMed

44.

Breuil V, Euller-Ziegler L (2006) Bisphosphonate therapy in rheumatoid arthritis. Jt Bone Spine Rev Rhum 73(4):349–354CrossRef

45.

Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D et al (2009) A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 11(6):185CrossRef

46.

Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann C-E, O’Connor PJ et al (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54(5):1410–1414CrossRefPubMed

47.

Valleala H, Laasonen L, Koivula M-K, Risteli J, Konttinen YT (2012) Effect of oral clodronate on structural damage and bone turnover in rheumatoid arthritis. Clin Exp Rheumatol 30(1):114–117PubMed

48.

Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50(5):1412–1419CrossRefPubMed

49.

Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E (2015) Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol Hoboken NJ 67(6):1456–1464CrossRef

Medicine Matters Rheumatology

Abstract